An innovative method to classify SERMs based on the dynamics of estrogen receptor transcriptional activity in living animals

Molecular Endocrinology

Volumn 24, Issue 4, 2010, Pages 735-744

  Rando, Gianpaolo ^a   Horner, David ^a   Biserni, Andrea ^b   Ramachandran, Balaji ^a   Caruso, Donatella ^a   Ciana, Paolo ^a   Komm, Barry ^c   Maggi, Adriana ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Transgenic Operative Products srl   (Italy)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAZEDOXIFENE; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; LASOFOXIFENE; OSPEMIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ALLOMETRY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYCLING; DISEASE MARKER; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ESTROGEN ACTIVITY; FEMALE; HORMONE SUBSTITUTION; HUMAN; IN VIVO STUDY; LONG TERM CARE; LOW DRUG DOSE; MATHEMATICAL ANALYSIS; MENOPAUSAL SYNDROME; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; OSCILLATION; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; SPATIAL DISCRIMINATION; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION INITIATION; WHOLE BODY IMAGING;

ANIMALS; BLOTTING, WESTERN; ESTRADIOL; ESTROGENS, CONJUGATED (USP); FEMALE; INDOLES; MICE; MICE, INBRED C57BL; OVARIECTOMY; PYRROLIDINES; RALOXIFENE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TETRAHYDRONAPHTHALENES; TRANSCRIPTION, GENETIC;

ANIMALIA; MUS;

EID: 77950385395     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2009-0514     Document Type: Article

References (56)

1. Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, Maggi A, Muramatsu M, Parker MG, Gustafsson JA 2006 International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev 58:773-781
2. Bolego C, Vegeto E, Pinna C, Maggi A, Cignarella A Selective agonists of estrogen receptor isoforms: new perspectives for cardiovascular disease. 2006 Arterioscler Thromb Vasc Biol 26:2192-2199
3. Imai Y, Kondoh S, Kouzmenko A, Kato S 2009 Regulation of bone metabolism by nuclear receptors. Mol Cell Endocrinol 310:3-10
4. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB 2003 Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 290:1729-1738
5. Straub RH The complex role of estrogens in inflammation. 2007 Endocr Rev 28:521-574
6. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S 2004 Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712
7. Johnson KA 2006 The SERM of my dreams. J Clin Endocrinol Metab 91:3754-3756
8. Tannen RL, Weiner MG, Xie D, Barnhart K 2007 Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy. Hum Reprod 22:1769-1777
9. Komm BS 2008 A new approach to menopausal therapy: the tissue selective estrogen complex. Reprod Sci 15:984-992
10. Jordan VC 2004 Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 5:207-213
11. Levenson AS, Kliakhandler IL, Svoboda KM, Pease KM, Kaiser SA, Ward 3rd JE, Jordan VC 2002 Molecular classification of selective oestrogen receptor modulators on the basis of gene expression profiles of breast cancer cells expressing oestrogen receptor α. Br J Cancer 87:449-456
12. Scafoglio C, Ambrosino C, Cicatiello L, Altucci L, Ardovino M, Bontempo P, Medici N, Molinari AM, Nebbioso A, Facchiano A, Calogero RA, Elkon R, Menini N, Ponzone R, Biglia N, Sismondi P, De Bortoli M, Weisz A 2006 Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem 98: 1163-1184
13. Kremoser C, Albers M, Burris TP, Deuschle U, Koegl M 2007 Panning for SNuRMs: using cofactor profiling for the rational discovery of selective nuclear receptor modulators. Drug Discov Today 12:860-869
14. Wu YL, Yang X, Ren Z, McDonnell DP, Norris JD, Willson TM, Greene GL 2005 Structural basis for an unexpected mode of SERM mediated ER antagonism. Mol Cell 18:413-424
15. Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS 1996 Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoterspecific action of these hormones. Mol Endocrinol 10:119-131
16. Lonard DM, Nawaz Z, Smith CL, O'Malley BW 2000 The 26S proteasome is required for estrogen receptor-α and coactivator turnover and for efficient estrogen receptor-α transactivation. Mol Cell 5:939-948
17. Jensen EV, Suzuki T, Numata M, Smith S, DeSombre ER 1969 Estrogen-binding substances of target tissues. Steroids 13:417-427
18. Saceda M, Lippman ME, Chambon P, Lindsey RL, Ponglikitmongkol M, Puente M, Martin MB 1988 Regulation of the estrogen receptor in MCF-7 cells by estradiol. Mol Endocrinol 2:1157-1162
19. Nardulli AM, Katzenellenbogen BS 1986 Dynamics of estrogen receptor turnover in uterine cells in vitro and in uteri in vivo. Endocrinology 119:2038-2046
20. Wu RC, Feng Q, Lonard DM, O'Malley BW 2007 SRC-3 coactivator functional lifetime is regulated by a phospho-dependent ubiquitin time clock. Cell 129:1125-1140
21. O'Malley BW 2009 The "fourth dimension" of gene transcription. Mol Endocrinol 23:587-589
22. Ciana P, Di Luccio G, Belcredito S, Pollio G, Vegeto E, Tatangelo L, Tiveron C, Maggi A 2001 Engineering of a mouse for the in vivo profiling of estrogen receptor activity. Mol Endocrinol 15:1104-1113
23. Ciana P, Raviscioni M, Mussi P, Vegeto E, Que I, Parker MG, Lowik C, Maggi A 2003 In vivo imaging of transcriptionally active estrogen receptors. Nat Med 9:82-86
24. Rando G, Biserni A, Ciana P, Maggi A 2010 Profiling of drug action using reporter mice and molecular imaging. Methods Mol Biol 602:79-92
25. Rando G, Casiraghi E, Arca S, Campadelli P, Maggi A, 2009 Automatic segmentation of mouse images. Proc 10th European Congress of International Society for Stereology, Bologna, Italy, 2009, p 60
26. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU 1994 Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:63-69
27. Kaufman L, Rousseeuw PJ 1990 Finding groups in data: an introduction to cluster analysis. New York: Wiley
28. Ashby J, Odum J, Foster JR 1997 Activity of raloxifene in immature and ovariectomized rat uterotrophic assays. Regul Toxicol Pharmacol 25:226-231
29. Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR 2005 Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 146:3999-4008
30. Voipio SK, Komi J, Kangas L, Halonen K, DeGregorio MW, Erkkola RU 2002 Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas 43:207-214
31. Ke HZ, Paralkar VM, Grasser WA, Crawford DT, Qi H, Simmons HA, Pirie CM, Chidsey-Frink KL, Owen TA, Smock SL, Chen HK, Jee WS, Cameron KO, Rosati RL, Brown TA, Dasilva-Jardine P, Thompson DD 1998 Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology 139:2068-2076
32. Yasui T, Uemura H, Takikawa M, Irahara M 2003 Hormone replacement therapy in postmenopausal women. J Med Invest 50: 136-145
33. McClung MR, Siris E, Cummings S, Bolognese M, Ettinger M, Moffett A, Emkey R, Day W, Somayaji V, Lee A 2006 Prevention of bone loss in post-menopausal women treated with lasofoxifene compared with raloxifene. Menopause 13:377-386
34. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S 1996 Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78-84
35. Hager GL, McNally JG, Misteli T 2009 Transcription dynamics. Mol Cell 35:741-753
36. Métivier R, Penot G, Hübner MR, Reid G, Brand H, Kos M, Gannon F 2003 Estrogen receptor-αdirects ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115: 751-763
37. Kang Z, Pirskanen A, Jänne OA, Palvimo JJ 2002 Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex. J Biol Chem 277:48366-48371
38. Bosisio D, Marazzi I, Agresti A, Shimizu N, Bianchi ME, Natoli G 2006 A hyper-dynamic equilibrium between promoter-bound and nucleoplasmic dimers controls NF-κB-dependent gene activity. EMBO J 25:798-810
39. Sung MH, Salvatore L, De Lorenzi R, Indrawan A, Pasparakis M, Hager GL, Bianchi ME, Agresti A 2009 Sustained oscillations of NF-κB produce distinct genome scanning and gene expression profiles. PLoS One 4:e7163
40. Stenoien DL, Patel K, Mancini MG, Dutertre M, Smith CL, O'Malley BW, Mancini MA 2001 FRAP reveals that mobility of oestrogen receptor-α is ligand- and proteasome-dependent. Nat Cell Biol 3:15-23
41. Valley CC, Métivier R, Solodin NM, Fowler AM, Mashek MT, Hill L, Alarid ET 2005 Differential regulation of estrogen-inducible proteolysis and transcription by the estrogen receptor α N terminus. Mol Cell Biol 25:5417-5428
42. Valley CC, Solodin NM, Powers GL, Ellison SJ, Alarid ET 2008 Temporal variation in estrogen receptor-α protein turnover in the presence of estrogen. J Mol Endocrinol 40:23-34
43. Gao H, Fält S, Sandelin A, Gustafsson JA, Dahlman-Wright K 2008 Genome-wide identification of estrogen receptor α-binding sites in mouse liver. Mol Endocrinol 22:10-22
44. Stavreva DA, Wiench M, John S, Conway-Campbell BL, McKenna MA, Pooley JR, Johnson TA, Voss TC, Lightman SL, Hager GL 2009 Ultradian hormone stimulation induces glucocorticoid receptor-mediated pulses of gene transcription. Nat Cell Biol 11:1093-1102
45. Clark AJ 1937 General pharmacology. In: Handbuch der experimentallen Parmakologie. Berlin: Springer Verlag
46. Stephenson RP 1956 A modification of receptor theory. Br J Pharmacol Chemother 11:379-393
47. Rang HP 2006 The receptor concept: pharmacology's big idea. Br J Pharmacol 147(Suppl 1):S9-S16
48. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB 2007 Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13
49. Kenakin TP 2008 Pharmacological onomastics: what's in a name? Br J Pharmacol 153:432-438
50. Galandrin S, Oligny-Longpré G, Bouvier M 2007 The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci 28:423-430
51. Turgeon JL, McDonnell DP, Martin KA, Wise PM 2004 Hormone therapy: physiological complexity belies therapeutic simplicity. Science 304:1269-1273
52. Pink JJ, Jordan VC 1996 Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 56:2321-2330
53. McDonnell DP 1999 The molecular pharmacology of SERMs. Trends Endocrinol Metab 10:301-311
54. McKenna NJ, O'Malley BW 2000 An issue of tissues: divining the split personalities of selective estrogen receptor modulators. Nat Med 6:960-962
55. Kenakin T 2005 New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 4:919-927
56. Caruso D, Scurati S, Maschi O, De Angelis L, Roglio I, Giatti S, Garcia-Segura LM, Melcangi RC 2008 Evaluation of neuroactive steroid levels by liquid chromatography-tandem mass spectrometry in central and peripheral nervous system: effect of diabetes. Neurochem Int 52:560-568